Table 3: Association of PMPMEase immunoreactivity with the pathologic features of colon cancer. Significantly higher PMPMEase immunoreactivities were observed in the different types, grades, and stages of colon cancers as shown by the means ± SEM versus normal tissues compared by ANOVA followed by Dunnet’s post test.

CharacteristicsPMPMEase Staining Intensity, N (%) Missing Mean Scores -value
1–100
Trace
101–200
Weak
201–300
Intermediate
301–400
Strong
401–500
Very strong

Normal11 (75.0)3 (25.0)0000
NAT4 (100)00000
Histology
Adenocarcinomas 7 (4.0)30 (17.1)57 (32.6)54 (30.9)20 (11.4)7 (4.0) 0.0001
Mucinous adenocarcinoma 1 (6.7)1 (6.7)6 (40.0)6 (40.0)1 (6.7)0
Papillary adenoma 0001 (100.0)00
Signet ring cell carcinoma 0001 (100.0)00
Pathological stage
 I2 (2.2)13 (14.1)33 (35.9)32 (34.8)10 (10.9)2 (2.2) 0.0001
 II5 (5.6)16 (18.0)26 (29.2)28 (31.5)11 (12.4)3 (3.4)
 III1 (16.7)1 (16.7)1 (16.7)2 (33.3)01 (16.7)
 IV01 (20.0)3 (60.0)001 (20.0)
Grade
 12 (5.7)5 (14.3)8 (22.9)18 (51.4)2 (5.7)0 0.0001
 24 (4.0)22 (21.8)37 (36.7)25 (24.8)10 (9.9)3 (3.0)
 2-3005 (50.0)5 (50.0)00
 32 (9.1)3 (13.6)10 (45.5)5 (22.7)2 (9.1)0
 Not determined01 (4.2)3 (12.5)9 (37.5)7 (29.2)4 (16.7)